Becker's Healthcare October 5, 2020
Katie Adams

Bristol Myers Squibb on Oct. 5 inked a $13.1 billion deal to buy Brisbane, Calif.-based drugmaker MyoKardia, aiming to diversify its drug portfolio beyond oncology medicines.

The New York City pharma giant will gain MyoKardia’s mavacamten, an experimental heart drug that treats obstructive hypertrophic cardiomyopathy. The treatment has not been approved by the FDA yet.

“We...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Mergers & Acquisitions / JV, Pharma, Pharma / Biotech, Trends
STAT+: After AI protein folding, David Baker’s lab identifies millions of smaller drug candidates
What Do Weight-Loss Drugs Mean for Diet Industry Built on Eating Less and Exercise?
Podcast #1: Doing Digital Deals in Life Sciences | Corporate Culture
BMS plans $1.5B in cuts through '25, with 2000-plus layoffs
Big Pharma's ROI for drug R&D saw 'welcome' rebound in 2023: report

Share This Article